[-] Show simple item record

dc.contributor.authorSchwartz, Kendraeng
dc.date.issued2001eng
dc.description.abstractRandomized controlled trials (RCTs) have demonstrated decreased vertebral and nonvertebral fracture rates in postmenopausal osteoporotic women taking a bisphosphonate (alendronate or risedronate). Hormone replacement therapy (HRT) also has some evidence for osteoporotic fracture prevention. Concurrent calcium and vitamin D may also prevent fractures. Physical exercise and smoking cessation have been associated with increased bone density, but fracture prevention has not been reported (Grade of Recommendation: B, some extrapolation from individual trials needed).eng
dc.identifier.urihttp://hdl.handle.net/10355/2816eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2001 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 50, no. 12 (December 2001)eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectfracture rateseng
dc.subjectbone mineral densityeng
dc.subjectdisease preventioneng
dc.subject.lcshOsteoporosis In Womeneng
dc.subject.lcshOsteoporosis -- Preventioneng
dc.subject.lcshBone densitometryeng
dc.subject.lcshEstrogen Therapeutic Useeng
dc.subject.meshOsteoporosis, Postmenopausal -- drug therapyeng
dc.titleWhat is the best approach to prevention and treatment of osteoporosis?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record